Adlai Nortye Group Ltd. American Depositary Shares (ANL)
NASDAQ
Closed
Sep 18, 2026
Day's Range
15.1352 wk Range
0.8790Overview - ANL - Adlai Nortye Group Ltd. American Depositary Shares
Key Statistics
Valuation
Enterprise Value
819.74M
P/E (Trailing)
‪-13.79‬
P/E (Forward)
‪-54.13‬
PEG Ratio
‪-54.13‬
Price / Sales (TTM)
‪56.81‬
Price / Book
‪4.77‬
EV / EBITDA
‪-37.86‬
Profitability
Profit Margin
‪-124.77%‬
Operating Margin
‪-44.18%‬
Return on Assets
‪-8.69%‬
Return on Equity
‪-20.22%‬
Ownership
Shares Outstanding
193.19M
Float
44.79M
Short % of Shares Outstanding
‪7.08%‬
Held by Insiders
‪1.06%‬
Held by Institutions
‪45.19%‬
Price stats
Beta
‪1.10‬
50-Day Avg
‪13.02‬
200-Day Avg
‪9.34‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
6 analysts
Average price target
‪$ 28.60‬Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ANL - Adlai Nortye Group Ltd. American Depositary Shares
Peers - ANL - Adlai Nortye Group Ltd. American Depositary Shares
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ANANLNASDAQAdlai Nortye Ltd. ADR999.45MMarket Cap+88.66%52-week change-13.79P/E (Trailing)‪-124.77%‬Profit Margin
- ARGXNASDAQArgenx SE61.58BMarket Cap+25.27%52-week change37.92P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.32.05BMarket Cap-91.57%52-week change41.68P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE24.13BMarket Cap-2.77%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.57BMarket Cap+17.02%52-week change18.34P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.02BMarket Cap+22.62%52-week change-17.62P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.37BMarket Cap+15.64%52-week change172.81P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - ANL - Adlai Nortye Group Ltd. American Depositary Shares
About
Adlai Nortye Ltd. ADR is the American Depositary Receipt representing shares of Adlai Nortye Ltd., a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapies. The company leverages its dual R&D presence in the United States and China to advance a robust…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
